Adeno-Associated Virus Antibody Profiles in Newborns, Children, and Adolescents

Roberto Calcedo, Hiroki Morizono, Lili Wang, Robert McCarter, Jianping He, David Jones, Mark L. Batshaw, James M. Wilson

Clinical and Vaccine Immunology · 2011 · 332 citations · 18 references

DOIFull text

Open access

Concepts

Abstract

Neutralizing antibodies (NAb) to an adeno-associated virus (AAV) vector due to previous natural infection with wild-type AAV can significantly limit gene transfer. NAb titers to AAV serotype 2 (AAV2) and AAV8 in human subjects (0 to 18 years) were studied. NAb prevalence is moderate at birth, decreases markedly from 7 to 11 months, and then progressively increases through childhood and adolescence.

References

18